FDA approved radioactive drugs used by nuclear medicine at the NIH clinical center for patient care procedures
Ended Awarded Last action
- Contract number
- 75N90023F00001
- Awardee
-
Cardinal Health 414, LLC UEI CWN9UGL3NCL9 Part of Cardinal Health, Inc.
- Awarding agency
-
NIH Clinical Center
National Institutes of Health, Department of Health and Human Services
- Obligated
- $830,000
Award facts
- Contract value 100% obligated
- $830,000.00 Current and potential, with all options
- Completion date 100% complete
-
- Current, with exercised options
- Potential, with all options
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- Set-aside
- No set-aside
- Competition
- Not Competed Only One Source
- Pricing
- Fixed Price with Economic Price Adjustment
- Place of performance
- Dublin, OH 43017, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Funding Only Action | $80,000 | |
| Original award | $750,000 |
About this award
Cardinal Health 414, LLC, a subsidiary of Cardinal Health, Inc. headquartered in Dublin, Ohio, was awarded a delivery order by the National Institutes of Health Clinical Center on October 1, 2022, for the supply of FDA-approved radioactive drugs used in nuclear medicine procedures for patient care. The contract, valued at $830,000 with a ceiling and ultimate completion date of September 30, 2026, operates under a fixed-price structure with economic price adjustment provisions. The performance location is Cardinal Health 414's facility in Dublin, Ohio. This delivery order was issued with no set-aside designation and represents part of Cardinal Health 414's broader portfolio of radiopharmaceutical supply contracts across federal healthcare agencies, demonstrating the company's established capability as a critical supplier of time-sensitive nuclear medicine products essential for diagnostic imaging and oncology treatment.
Cardinal Health 414 specializes in the manufacturing, testing, and distribution of radiopharmaceuticals and medical isotopes, maintaining FDA and Nuclear Regulatory Commission compliance while managing the stringent handling and transportation requirements associated with radioactive materials. The company's federal customer base includes the Department of Veterans Affairs across multiple Veterans Integrated Service Networks, the Defense Health Agency, and the NIH, with existing indefinite delivery contracts and blanket purchase agreements establishing long-term supply relationships. The radiopharmaceutical products supplied under such arrangements include common diagnostic tracers such as technetium-99m and fluorine-18 fluorodeoxyglucose (FDG), as well as specialized therapeutic products like Xofigo for prostate cancer treatment, enabling the federal healthcare system to maintain consistent access to essential nuclear medicine supplies with delivery turnaround times often measured in hours due to the short half-lives of radioactive isotopes.
Quick answers
Who was awarded contract 75N90023F00001?
75N90023F00001 was awarded to Cardinal Health 414, LLC by NIH Clinical Center (National Institutes of Health) on October 1, 2022.
How much is contract 75N90023F00001 worth?
The government has obligated $830,000 on 75N90023F00001.
Is contract 75N90023F00001 an order under another contract?
Yes. 75N90023F00001 is a delivery order under 75N90023D00003, an indefinite delivery contract.
Was contract 75N90023F00001 competed?
The extent of competition for 75N90023F00001 was not competed.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award